

NEWSLETTER



MAH INVOICING PROCESS FOR 2022

Following the OSMR General Assembly's decision on June 30th, 2021, **the operational fee for 2022 for the National Medicines Verification System (NMVS) will remain the same as for this year: 10,500 EUR/MAH.**

As you have been accustomed from previous years, **the invoicing process will start during the month of September and the payment deadline is set for December 20th, 2021.**



OSMR would like to acknowledge the collaborative relationship that has been consolidated with the MAHs and the OBP companies since the Go-Live of the serialisation project.

Apart from having ensured the monetary backbone of the project and also the integration of the safety features on the medicines' packs, **the MAHs have also engaged in the process of minimizing the number of false alerts generated in the system.**

The high amount of work that these companies have put into this project is visible in the milestones that have been set up and reached until this point in time, thus succeeding in creating a safe and secure medicines' market.

EUROPEAN HUB

The European Hub release 1.9 was successfully deployed to PROD environment on June 5th, 2021.

Among the new features that have been added to improve the overall operativity of the EU Hub, one important upgrade is the development of the system that will allow the integration of the Alert Management System (AMS).

NATIONAL MEDICINES VERIFICATION SYSTEM – NMVS

The planning for the deployment of the system's new versions: NMVS Core – 1.09 & Reporting Tool – 1.06 for all the countries using Arvato as the blue-print provider remains unchanged – November 2021.

jUAT (JOINT USER ACCEPTANCE TESTING)

In order for the deployment of the system's new versions: NMVS Core – 1.09 & Reporting Tool – 1.06 to be successful, a joint User Acceptance Testing phase needs to be executed.

In this case, the countries that participated in the above-mentioned process are **Latvia, Romania, Hungary, Portugal and the Netherlands**.

From the OSMR Team, the nominated colleague involved in the testing is **Dan Vişoiu** – contributing as a **Test Engineer**.

The novelty brought by this jUAT is the introduction of the automated testing concept for the acceptance tests. And as **functionality upgrades entailed by this new release, the most important ones are performance improvement, new reports, bug fixes**.

The preparation phase for the jUAT took place between May and July, during which weekly alignment meetings were held to have a clear common understanding of the process and also to fine tune certain technical topics with the help of focus groups.

During the month of July there were 3 weeks of testing:

12 – 17.07.2021 dry-run

18 – 23.07.2021 Formal Execution Core NMVS 1.09.003

25 – 30.07.2021 Formal Execution Reporting Tool 1.06.004

As a result of the testing, several defects have been identified and have already been undertaken by Arvato to be fixed.

After the jUAT is finalized, the new system's versions are to be deployed in all countries having Arvato as the blue-print provider and that will be **followed by the Inter-Operability Testing (IOT) between EMVO, the Arvato Ecosystem and the Solidsoft Ecosystem**.

NMVS END-USERS' V5 INTERFACE

In view of the continuous improvement of the system's general performance, upgrading the End-Users' interfaces so that they can connect to the NMVS is part of this process.

As it has been previously mentioned during the Software Providers' Online Gatherings, **the V3 version of the NMVS will be disconnected in April 2022, when the V5 version is to be deployed**.

Previous experience has shown us that upgrading from one version to the other has proven to be a lengthy process and it is of the utmost importance that the Software Providers are informed about this and can plan the necessary actions.

Our recommendation is that **the migrating process to the V4 interface be done as soon as possible using the documentation that Arvato has made available on the portal: <https://www.sws-nmvs.eu>**

